Eikon Therapeutics, Inc. Common Stock vs. Krystal Biotech, Inc. Common Stock
EIKN
Eikon Therapeutics, Inc. Common Stock
$10.83 -1.19%
VS KRYSKrystal Biotech, Inc. Common Stock
$355.49 -4.30%
Krystal Biotech, Inc. Common Stock (KRYS) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| EIKN | KRYS | |
|---|---|---|
| Market Cap | $593.65 million | $11.00 billion |
| Revenue (TTM) | — | $440.48 million |
| Net Income (TTM) | — | $241.47 million |
KRYS leads on 1 of 1 size & scale factors.
Valuation
| EIKN | KRYS | |
|---|---|---|
| P/E Ratio | — | 44.55 |
| Price / Book | 1.27 | 8.09 |
| Price / Sales | — | 24.96 |
EIKN leads on 1 of 1 valuation factors.
Profitability
| EIKN | KRYS | |
|---|---|---|
| Net Margin | — | 54.82% |
| Return on Equity | — | 17.77% |
EIKN and KRYS split the profitability factors evenly.
Risk & Sentiment
| EIKN | KRYS | |
|---|---|---|
| Short Interest | 1.60% | 0.11% |
KRYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: EIKN overview, EIKN financials, KRYS overview, KRYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.